Tokyo, Japan

Ryutaro Fukui

This inventor holds 1 USPTO granted patent. Top assignee: The University of Tokyo. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ryutaro Fukui. Retrieved from https://idiyas.com/inventor/ryutaro-fukui

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ryutaro Fukui: Innovator in Antibody Research

Introduction

Ryutaro Fukui is a prominent inventor based in Tokyo, Japan. He is known for his significant contributions to the field of pharmaceutical research, particularly in the development of novel antibodies.

Latest Patents

Fukui holds a patent for an "Anti-TLR9 antibody, pharmaceutical composition, and kit." This invention provides a novel antibody targeting TLR9, which plays a crucial role in immune response. His innovative work in this area has the potential to advance therapeutic options for various diseases.

Career Highlights

Fukui is affiliated with The University of Tokyo, where he conducts his research and development activities. His work has garnered attention for its implications in immunology and therapeutic applications.

Collaborations

Fukui collaborates with notable colleagues, including Yusuke Murakami and Kensuke Miyake. Their combined expertise enhances the research efforts and contributes to the advancement of their projects.

Conclusion

Ryutaro Fukui's contributions to antibody research exemplify the innovative spirit of modern science. His work not only advances academic knowledge but also holds promise for future medical applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…